About Zynerba Pharma
Zynerba Pharma is a company based in Devon (United States) founded in 2007 was acquired by Harmony Biosciences in August 2023. Zynerba Pharma has raised $13 million across 6 funding rounds from investors including Harmony Biosciences, NIH and HHS. The company has 27 employees as of March 31, 2023. Zynerba Pharma offers products and services including Zygel TM. Zynerba Pharma operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter Devon, United States
- Employees 27 as on 31 Mar, 2023
- Stage Public
-
Sectors
HealthcareTechnology
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Zynerba Pharmaceuticals, Inc.
-
Annual Revenue
$7.25 K (USD)-97as on Dec 31, 2016
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$13 M (USD)
in 6 rounds
-
Latest Funding Round
Not available
-
Investors
Harmony Biosciences
& 5 more
-
Employee Count
27
as on Mar 31, 2023
-
Acquired by
Harmony Biosciences
(Aug 14, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Zynerba Pharma
Zynerba Pharma offers a comprehensive portfolio of products and services, including Zygel TM.
Transdermal cannabinoid treatment for neuropsychiatric disorders in rare conditions.
People of Zynerba Pharma
Unlock access to complete
Unlock access to complete
Funding Insights of Zynerba Pharma
Zynerba Pharma has successfully raised a total of $13M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Zynerba Pharma
Zynerba Pharma has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Harmony Biosciences, NIH and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are directed toward North American opportunities.
|
Locked | Locked | Locked | |
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Scientific research on drug use and addiction is supported.
|
Locked | Locked | Locked |
Investor details for Zynerba Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Zynerba Pharma
Investment portfolio details for Zynerba Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Zynerba Pharma
Detailed financials for Zynerba Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Zynerba Pharma Comparisons
Peer comparison for Zynerba Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Zynerba Pharma
Zynerba Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| Locked | Locked | Locked |
Gene and protein therapies are developed for treating various diseases.
|
Detailed competitors of Zynerba Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Zynerba Pharma
Complete news archive for Zynerba Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Zynerba Pharma
Zynerba Pharma was founded in 2007.
Zynerba Pharma is headquartered in Devon, United States. It is registered at Devon, Pennsylvania, United States.
Jeffrey M Dayno is the current CEO of Zynerba Pharma.
Zynerba Pharma is a funded company, having raised a total of $13M across 6 funding rounds to date.
As of Mar 31, 2023, the latest employee count at Zynerba Pharma is 27.
Annual revenue of Zynerba Pharma is $7.25K as on Dec 31, 2016.
Zynerba Pharmaceuticals (formerly known as AllTranz) is focused on developing synthetic cannabinoid therapeutics for transdermal delivery. Using its proprietary transdermal technologies, it has developed a controlled delivery of therapeutic levels of two cannabinoids cannabidiol (CBD) and Tetrahydrocannabinol (THC). Its lead candidate ZYN002, a CBD gel, is being studied in refractory epilepsy, FXS, and osteoarthritis. It is also developing ZYN001 which uses pro-drug of THC in a transdermal patch to deliver THC and is currently being studied in fibromyalgia and peripheral neuropathic pain.
Zynerba Pharma's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
Zynerba Pharma offers Zygel TM.
Zynerba Pharma has 6 investors. Key investors include Harmony Biosciences, NIH, HHS, Perceptive Advisors, and Lincoln Park Capital.